New CDMO PMI BioPharma Launches Research Lab and Mfg Facilities
PMI BioPharma Solutions (PMI Bio), a new contract development and manufacturing organization formed in January of 2018, has established research and manufacturing operations at multiple sites located in Nashville and Celina, Tennessee. The sites offer services from targeted protein research to Phase III clinical trial supplies.
(PMI Bio) began as an internal research, development, and manufacturing site for Berg, LLC, a Framingham, Massachusetts-based biopharmaceutical company. PMI Bio subsequently spun off from Berg and expanded to offer a full range of research and development services for drug discovery and development.
PMI Bio’s protein sciences’ services express and purify proteins and develop assays around protein targets using nuclear magnetic resonance, surface plasmon resonance, crystallography, isothermal titration calorimetry, time-resolved fluorescence resonance energy transfer, differential scanning fluorometry, and more. The company provides high throughput library screens and design, develops and tests drugs in vitro and in vivo. PMI Bio’s clinical trial production capabilities include bulk liquid manufacturing, aseptic fill/finish and non-aseptic fill/finish for small to medium-scale batches.
“While PMI Bio can offer multiple research and development services for clients, our two distinct areas of expertise are fragment-based drug discovery services and aseptic manufacturing. PMI Bio also has years of expertise in nanosuspensions using microfluidization technologies,” said CEO David Sunseri, PhD, in a September 13, 2018 company statement.
Source: PMI BioPharma Solutions